PMGC Holdings (ELAB) Net Income (2022 - 2026)
PMGC Holdings' (ELAB) quarterly Net Income came in at -$4.3 million in Q2 2026, down 25245.61% year-over-year from N/an in Q2 2025, and down 15.67% quarter-over-quarter from -$3.7 million in Q1 2026.
Analysis
PMGC Holdings (ELAB) Net Income (2022 - 2026) Analysis & Trends
PMGC Holdings has disclosed Net Income across 5 years of filings, most recently posting -$4.3 million for Q2 2026.
- In Q2 2026, Net Income fell 25245.61% year-over-year to -$4.3 million; the TTM figure through Jun 2026 stood at -$12.9 million (down 516.05% YoY), while the FY2025 annual figure was $8.4 million, up 476.26% from the prior year.
- Net Income came in at -$4.3 million for Q2 2026 at PMGC Holdings, down from -$3.7 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $1.1 billion in Q4 2022 to a low of -$469.3 million in Q3 2022.
- Average Net Income over 5 years is $38.9 million, with a median of -$1.4 million recorded in 2023.
- Year-over-year, Net Income jumped 100.75% in 2025 and sank 25245.61% in 2026.
- Over 5 years, Net Income stood at $1.1 billion in 2022, then slumped by 100.1% to -$1.1 million in 2023, then soared by 80.06% to -$216910.0 in 2024, then slumped by 1070.9% to -$2.5 million in 2025, then slumped by 69.65% to -$4.3 million in 2026.
- Per Business Quant data, the three most recent Net Income figures were -$4.3 million in Q2 2026, -$3.7 million in Q1 2026, and -$2.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.26 Bn | 193.27 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 179.66 Bn | 176.48 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 131.52 Bn | 123.67 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.77 Bn | 73.78 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.15 Bn | 55.97 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 53.55 Bn | 48.41 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.38 Bn | 30.07 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.68 Bn | 30.40 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.12 Bn | 29.12 Bn | 1.16 Mn | -290.61 Mn |
| 10 | PMGC Holdings | 2.29 Mn | -16.50 Mn | 385,691.00 | -4.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.31 Mn |
| Mar 31, 2026 | -3.72 Mn |
| Dec 31, 2025 | -2.54 Mn |
| Sep 30, 2025 | -2.33 Mn |
| Jun 30, 2025 | 17,135.00 |
| Mar 31, 2025 | -27,644.00 |
| Dec 31, 2024 | -216,910.00 |
| Sep 30, 2024 | -1.87 Mn |
| Jun 30, 2024 | -2.30 Mn |
| Mar 31, 2024 | -1.68 Mn |
| Dec 31, 2023 | -1.09 Mn |
| Sep 30, 2023 | -791,239.00 |
| Jun 30, 2023 | -1.06 Mn |
| Mar 31, 2023 | -841,282.00 |
| Dec 31, 2022 | 1.11 Bn |
| Sep 30, 2022 | -469.32 Mn |